|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0013216,
umls-concept:C0018943,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0039796,
umls-concept:C0055598,
umls-concept:C0086409,
umls-concept:C0087111,
umls-concept:C0200627,
umls-concept:C0205282,
umls-concept:C1096776,
umls-concept:C1257890,
umls-concept:C1332225,
umls-concept:C1413947,
umls-concept:C1707455,
umls-concept:C2603343,
umls-concept:C2728259
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
1998-8-5
|
|
pubmed:abstractText |
To compare standard chemotherapy CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) with the regimen CHOP/VIA (VP-16, iphosphamide and cytarabine) in terms of response to therapy, response duration, survival and toxicity in patients with aggressive lymphoma.
|
|
pubmed:language |
spa
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0025-7753
|
|
pubmed:author |
pubmed-author:AlcaláAA,
pubmed-author:Alvarez-CarmonaA MAM,
pubmed-author:BesserBB,
pubmed-author:CarbonellFF,
pubmed-author:ContrerasEE,
pubmed-author:FontanillasMM,
pubmed-author:García-CondeJJ,
pubmed-author:HernandoAA,
pubmed-author:López-GuillermoAA,
pubmed-author:LeónPP,
pubmed-author:MaldonadoJJ,
pubmed-author:MontserratEE,
pubmed-author:Sancho-TelloRR,
pubmed-author:ZubizarretaAA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
9
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
601-4
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9656196-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9656196-Cyclophosphamide,
pubmed-meshheading:9656196-Cytarabine,
pubmed-meshheading:9656196-Data Interpretation, Statistical,
pubmed-meshheading:9656196-Doxorubicin,
pubmed-meshheading:9656196-Etoposide,
pubmed-meshheading:9656196-Female,
pubmed-meshheading:9656196-Humans,
pubmed-meshheading:9656196-Ifosfamide,
pubmed-meshheading:9656196-Lymphoma, Follicular,
pubmed-meshheading:9656196-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:9656196-Lymphoma, Large-Cell, Immunoblastic,
pubmed-meshheading:9656196-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9656196-Male,
pubmed-meshheading:9656196-Middle Aged,
pubmed-meshheading:9656196-Prednisone,
pubmed-meshheading:9656196-Prognosis,
pubmed-meshheading:9656196-Survival Analysis,
pubmed-meshheading:9656196-Time Factors,
pubmed-meshheading:9656196-Vincristine
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
|
|
pubmed:affiliation |
Servicio de Hematología, Hospital Clínic i Provincial, Villarroel, Barcelona.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
English Abstract,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
